About this trial
A multicenter, retrospective study conducted in male and female population infected with HBV or HCV in east China. HCV part, study will enroll 500 HCV antibody positive and HCV RNA positive patients during 2020.7-2023.12 and then observe the characteristics, duration from diagnosis to treatment, treatment rate and sustained virologic response (SVR12) among eligible female and male patients. HBV part, study will enroll 2000 HBsAg positive patients during 2016.7-2019.12 and then observe the clinical characteristics, natural history, duration from diagnosis to treatment, treatment rate and adherence among eligible female and male patients.
Eligibility criteria
Qualifiers
≥18 years old
serum HBsAg positive for >6 months
Treatment naïve or,
Patients who had been previously treated for HBV but discontinued for at least 1 year before enrollment
Disqualifiers
HBV/HCV Co-infection
HIV
History of hepatic decompensation or hepatocellular carcinoma
Other carcinoma
Trial design
Treatments tested in this trial
- Not listed